Screening and functional validations of APP, PSEN1, and PSEN2 mutations from PUMCH dementia cohort
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
To the Editor: PSEN1, PSEN2, and APP have been verified as causative genes for familial Alzheimer’s disease (AD). Meta-analysis suggests that patients with AD causative mutations may develop symptoms at a younger age (average age of onset at 46.2 years).[1] However, some cases are late-onset or sporadic. Therefore, studies confined to early-onset or familial AD populations are incomprehensive, leading to an incomplete description of the genetic AD spectrum. In the pathogenesis of AD, amyloid beta (Aβ) is derived from amyloid precursor protein (APP) through proteolysis via the β-secretase and γ-secretase complex, whereas presenilin-1 (PS1) and presenilin-2 (PS2) are critical components of γ-secretase complex.[2] Previous research on transgenic animal models or transfected cells indicated that mutations could increase the level of Aβ (especially Aβ42) or Aβ42/Aβ40 ratio. This study aimed to screen for pathogenic mutations in a large sample of Chinese population with dementia (Peking Union Medical College Hospital [PUMCH] dementia cohort) and determine the functional effect of the identified mutation by in vitro study. Participants were recruited from the PUMCH dementia cohort in Beijing, China. This study was approved by the Ethics Committee of PUMCH (No. JS2810) and registered at ClinicalTrials.gov (NCT05023564). Written informed consent was obtained from all participants and their legal guardians. A total of 1277 participants diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) were enrolled, including those with AD, frontotemporal dementia, vascular dementia, dementia with Lewy bodies, mixed dementia, and dementia with leukoencephalopathy. Data, including detailed clinical information, physical examination, and family history, were collected. All patients underwent standard blood tests, neuropsychological assessments, and magnetic resonance imaging (MRI), with detailed protocols provided in the Supplementary Materials, https://links.lww.com/CM9/C822. DNA was extracted from the peripheral blood of participants in the Clinical Biobank (ISO 20387) of PUMCH, which has standard quality control. Next-generation sequencing was performed on 1277 patients recruited between 2007 and 2019, among which, 267 underwnt whole exome sequencing (WGS), and the remaining 1010 underwent targeted panel sequencing (targeting on 278 dementia-related genes, including APP, PSEN1, and PSEN2). Next-generation sequencing technology was performed on Illumina HiSeq (Illumina Inc., San Diego, USA). All detected variants were verified by Sanger sequencing and classified as pathogenic, likely pathogenic, or of uncertain significance according to the American College of Medical Genetics and Genomics (ACMG) standards and searched in the database of Alzforum and PubMed to determine whether they were novel or reported. The inclusion criteria for analysis were based on bioinformatics analysis: filtering was restricted to causative AD genetic mutations; variants previously reported to be causative AD mutations; non-synonymous variants causing missense, frameshift, or splicing mutations; the frequency of variants in the general population (1000 Genomes project, Exome Aggregation Consortium [ExAC] database, 1000 healthy Chinese controls) must be
Fields of Study & Subjects
Alzheimer's disease research and treatments
Dementia and Cognitive Impairment Research
Amyotrophic Lateral Sclerosis Research
Publication details
- Journal / source
- Chinese Medical Journal
- Volume
- 139
- Issue
- 14
- Pages
- 2204–2206
- Publication date
- 31 March 2026
- Language
- EN